Pharmacy benefit managers (PBMs) are being targeted yet again by the government. James Comer (R-Ky), House Committee on Oversight and Accountability chairman, launched an investigation Wednesday into PBMs and their “tactics that are harming…
Continue Reading
The biggest threats employers are facing right now include high-cost pharmacy claims, medical inflation and million dollar treatments being approved by the Food and Drug Administration, a Wednesday survey found.
The report was conducted by…
Editor’s note: This story is based on an interview at Abarca Forward, a conference that was hosted by Abarca Health, a pharmacy benefit manager last week in San Juan, Puerto Rico. MedCity News’ Editor-in-Chief…
Continue Reading
Mark Cuban Cost Plus Drug Company (MCCPDC) is partnering with diabetes and chronic disease management company Diathrive Health to provide lower-cost prescription medication and diabetes testing supplies to Diathrive’s members. Diathrive Health offers individuals and…
Continue Reading
Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca Health, a pharmacy benefit manager. MedCity News’ Editor-in-Chief Arundhati Parmar and Senior Reporter Katie Adams were invited to attend and speak at the conference. All travel and related expenses for…
Continue Reading
Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca, a pharmacy benefit manager. MedCity News’ Editor-in-Chief Arundhati Parmar and Senior Reporter Katie Adams were invited to attend and speak at the conference. All travel and related expenses for the team were covered by Abarca. However, company officials had no input in editorial coverage.
The U.S. healthcare systems spent a whopping $301 billion on specialty drugs in 2021, a 43% increase since 2016. These specialty drugs accounted for half of the year’s total drug spending, and the list prices for specialty…
Pharmacy Benefit Managers (PBMs) took a hit from lawmakers during a Thursday hearing held by the Senate Commerce Committee, with some questioning why the drug middlemen are even necessary.
“The way I see the situation on PBMs, I don’t know why the hell they even exist,” said Sen. Jon Tester, D-Montana. “They were set up with all the right reasons … But what I see them doing in my state, I don’t think the consumer gets much benefit and they’re shutting down small businesses on main street right and left and those are called our local neighborhood pharmacies.” The hearing discussed how…
Editor’s note: This story is based on discussions at Abarca Forward, a conference in San Juan, Puerto Rico, hosted by Abarca, a pharmacy benefit manager. MedCity News’ Editor-in-Chief Arundhati Parmar and Senior Reporter Katie Adams were invited to attend and speak at the conference. All travel and related expenses for the team were covered by Abarca. However, company officials had no input in editorial coverage.
In order for the U.S. healthcare system to operate smoothly, various stakeholders must cooperate with one another and share data seamlessly. But this notion is far from being achieved — the industry is still seriously plagued by…
